ライフサイエンスコーパス: lipid mediator

1 kotriene B4 (LTB4), a potent proinflammatory lipid mediator.

2 and upregulation of specialized proresolving lipid mediators.

3 lethanolamines (NAEs), a family of bioactive lipid mediators.

4 munity and the presence of many cytokine and lipid mediators.

5 ratio of proresolving versus proinflammatory lipid mediators.

6 ammatory responses through the production of lipid mediators.

7 re obtained with candidate pollen-associated lipid mediators.

8 d by a switch from inflammatory to resolving lipid mediators.

9 g cytokines, chemokines, growth factors, and lipid mediators.

10 LTB4, LTC4, LTD4, and LTE4) are inflammatory lipid mediators.

11 on, hydrolysis and oxidation of these potent lipid mediators.

12 oxygenated fatty acids, including well-known lipid mediators.

13 is represents a new biosynthetic pathway for lipid mediators.

14 trates that these enzymes use for generating lipid mediators.

15 ion of lipid droplets and alter synthesis of lipid mediators.

16 g the therapy-induced surge of cytokines and lipid mediators.

17 e to inappropriate synthesis of proresolving lipid mediators.

18 The proresolving lipid mediator, 15-epi lipoxin A4 (15-epi LXA4), plays a

19 s lysophosphatidic acid (LPA), a pleiotropic lipid mediator acting on specific GPCRs.

20 roup IVA (cPLA2alpha) activation, are potent lipid mediators also attributed to acute and chronic inf

21 ses including allergy is their production of lipid mediators, among which only omega-6 (omega-6) arac

22 rted IEC expulsion that was coordinated with lipid mediator and cytokine production and lytic IEC dea

23 ine kinase (SphK) is the major source of the lipid mediator and G protein-coupled receptor agonist sp

24 f multidisciplinary research focused on this lipid mediator and the application of S1PR-targeted drug

25 d by the immune system, including cytokines, lipid mediators and growth factors, and can also directl

26 e potent producers of inflammation-resolving lipid mediators and induced the repair response of synov

27 spite their recognition as anti-inflammatory lipid mediators and regulators of ion channels, little i

28 fatty acid epoxides as new mast cell-derived lipid mediators and show that they are produced by PAF-A

29 s have investigated specialized proresolving lipid mediators and their relation to other lipid mediat

30 transport proteins may alter the traffic of lipid mediators and thus affect their signaling and enzy

31 Excessive adipocyte lipolysis generates lipid mediators and triggers inflammation in adipose tis

32 , the production of specialized proresolving lipid mediators, and their importance for mesenchymal st

33 animals and the so-called pollen-associated lipid mediators are codelivered with the allergens and c

34 alyses of polyunsaturated fatty acid-derived lipid mediators are required to determine possible diver

35 is, we have identified this chemo-protective lipid mediator as arachidonic acid (AA).

36 eing associated with alteration of bioactive lipid mediators as assessed by mass spectrometry.

37 excretory/secretory products but few related lipid mediators as established by metabololipidomic anal

38 Lipid mediators, as well as cytokines, help establish a

39 PH domain also binds to phosphatidic acid, a lipid mediator associated with microneme exocytosis.

40 Oxylipids are potent lipid mediators associated with inflammation-induced col

41 lammatory perturbation of plasma protein and lipid mediators associated with TB in patients in China

42 In this context, we discuss lipid mediators associated with the maintenance of healt

43 ism of arachidonic acid results in bioactive lipid mediators beyond prostaglandins that could signifi

44 ies of enzymes and receptors responsible for lipid mediator biosynthesis and function.

45 onooxygenases are believed to participate in lipid mediator biosynthesis and/or their local inactivat

46 henotype, but its role in SPM production and lipid mediator biosynthesis in general is elusive.

47 portant enzymes for specialized proresolving lipid mediator biosynthesis, resulted in a loss of thera

48 Here we report a novel class of lipid mediators biosynthesized in human retinal pigment

49 ia, lower PON1 activity and higher bioactive lipid mediators (BLM), as well as a dysregulated hepatic

50 monstrate that RvE1 functions as a prorepair lipid mediator by increasing intestinal epithelial cell

51 This study focuses on the induction of lipid mediators by HMGB1 and HMGB1 plus C1q and their re

52 and growth factors using an xMAP method, and lipid mediators by liquid chromatography-tandem mass spe

53 e debris-induced surge of both cytokines and lipid mediators by macrophages.

54 Biosynthesis of proresolving lipid mediators by vascular cells and tissues.

55 ted in part by long-chain fatty acid-derived lipid mediators called specialized proresolving mediator

56 e an active process involving a new genus of lipid mediators, called "specialized proresolving lipid

57 nversely, impaired release of FFAs and other lipid mediators can also disrupt key cellular signaling

58 h many soluble factors such as cytokines and lipid mediators can influence ILC2, direct interaction o

59 that production of specialized proresolving lipid mediators contribute to improved mesenchymal strom

60 oxin A4 (LXA4), a specialized, proresolution lipid mediator, could increase neutrophil phagocytic act

61 Resolvins, a class of lipid mediators, counteract this effect, representing an

62 Both lipid mediators derive from the same pathway, in which a

63 The first total synthesis of a lipid mediator derived from natural omega-3-fatty acid d

64 D1 (RvD1), a unique family of pro-resolving lipid mediator derived from the omega-3 polyunsaturated

65 Lipid mediators derived from 5-lipoxygenase (5-LO) metab

66 ng prostaglandins (PG) and leukotrienes, are lipid mediators derived from arachidonic acid.

67 GD2) and cysteinyl leukotrienes (cysLTs) are lipid mediators derived from mast cells, which activate

68 ion is mediated by specialized pro-resolving lipid mediators derived from omega-3 fatty acids or arac

69 Eicosanoids, an important class of lipid mediators derived from polyunsaturated fatty acids

70 al in this signalling process is an array of lipid mediators derived from polyunsaturated fatty acids

71 Recent evidence suggests that specialized lipid mediators derived from polyunsaturated fatty acids

72 imbalance between inflammatory and resolving lipid mediators during atheroprogression.

73 (SPMs) and proinflammatory and prothrombotic lipid mediators during DVT progression in mice.

74 ysis revealed that various anti-inflammatory lipid mediators (e.g., docosahexaenoic acid) were increa

75 and post-treatment plasma were analyzed for lipid mediators (eg, eicosanoids and endocannabinoids) a

76 sma fasting glucose, serum hsCRP, and plasma lipid mediators (eicosanoids and related analogs) were m

77 The sEH degrades natural analgesic lipid mediators, epoxy fatty acids (EpFAs), therefore it

78 s sphingosine-1-phosphate (S1P), a bioactive lipid mediator essential for inflammation.

79 These lipid mediators exert anti-inflammatory and pro-resolvin

80 pholipids and production of pro-inflammatory lipid mediators (for example, leukotrienes and prostagla

81 rostaglandins) and specialized pro-resolving lipid mediators (for example, resolvins and lipoxins) th

82 MDM, however, the biosynthetic machinery for lipid mediator formation was independent of V-ATPase act

83 Sphingosine 1-phosphate (S1P) is a lipid mediator formed by the metabolism of sphingomyelin

84 Leukotrienes (LTs) are proinflammatory lipid mediators formed from arachidonic acid in a 2-step

85 PGs are lipid mediators formed in response to certain circulatin

86 new method for extracting RNA, protein, and lipid mediators from a single tissue specimen.

87 Sphingosine 1-phosphate (S1P) is a bioactive lipid mediator generated when a cell membrane or its com

88 Resolvins are lipid mediators generated by leukocytes during the resol

89 Sphingosine 1-phosphate (S1P) is a bioactive lipid mediator, generated by sphingosine kinases (SPHK1

90 ng the biomimetic properties of proresolving lipid mediators has not been demonstrated.

91 Because oxidized lipid mediators have also been implicated in the pathoge

92 Specialized proresolving lipid mediators have emerged as powerful modulators of i

93 Lipid mediators, highly bioactive compounds synthesized

94 , and lipoxins) with respect to inflammatory lipid mediators (i.e., leukotriene B4 and PGs) in omenta

95 Therefore, we hypothesized that lesional lipid mediator imbalance favors atheroprogression.

96 a potent anti-inflammatory and proresolution lipid mediator in several animal models of inflammation,

97 ing the milieu of inflammatory cytokines and lipid mediators in AERD has been conflicting.

98 into the as yet unrevealed action of PFOS on lipid mediators in affecting testicular functions.

99 Profiling lipid mediators in biopsies and suction blister fluid ca

100 ings support a unique profile of specialized lipid mediators in bone marrow that contribute to a feed

101 fatty acids for use as energy substrates or lipid mediators in cellular processes.

102 ing impaired formation of these proresolving lipid mediators in conditions characterized by dysfuncti

103 the idea of a role of these key enzymes and lipid mediators in host survival during anthrax disease.

104 ignaling induces the production of bioactive lipid mediators in macrophages.

105 Specialized proresolving lipid mediators in patients with coronary artery disease

106 that contribute to the modulatory actions of lipid mediators in peripheral nociceptive signaling.

107 bility to produce cytokines, chemokines, and lipid mediators in response to subsequent TLR stimulatio

108 Lipid mediators in sinonasal tissue were measured by mas

109 Their presence as the dominant lipid mediators in spontaneous labor at term portends a

110 poxygenase- and lipoxygenase-pathway-derived lipid mediators in spontaneous labor with remarkable pro

111 sphatidic acid (PA), and both DAG and PA are lipid mediators in the cell.

112 f platelet activating factor (PAF), a potent lipid mediator, in human PMNs.

113 Analgesic lipid mediators include endogenous agonists of cannabino

114 Proinflammatory lipid mediators including prostaglandin E2 (PGE2) contri

115 rocess, governed by specialized proresolving lipid mediators, including lipoxins, resolvins, maresins

116 nd counter-regulated inflammation-initiating lipid mediators, including prostaglandins.

117 to calculate scores for distinct families of lipid mediators, including resolvins, lipoxins, prostagl

118 Lipid mediators influence immunity in myriad ways.

119 PGE2 is a potent lipid mediator involved in maintaining homeostasis but a

120 ophosphatidic acid (LPA) is an extracellular lipid mediator involved in many physiological functions

121 ukotrienes, which are potent proinflammatory lipid mediators involved in chronic inflammatory disease

122 and giving rise to the generation of diverse lipid mediators involved in inflammatory conditions.

123 These findings demonstrate the diversity of lipid mediators involved in maintaining tissue homeostas

124 ebrafish and discovered that prostaglandins, lipid mediators involved in many physiological functions

125 ns (D-series and E-series) are pro-resolving lipid mediators involved in resolution and tissue repair

126 S)-hydroxyeicosatetraenoic acid [12(S)-HETE] lipid mediator is among inflammatory molecules that are

127 upplementation with specialized proresolving lipid mediators is an important therapeutic strategy in

128 Cytokines and lipid mediators known as eicosanoids play key roles in r

129 PUFA) and the main precursor to the class of lipid mediators known as eicosanoids.

130 IL-6 secretion and production of the lipid mediator leukotriene C(4) were unaffected.

131 talyzes the formation of the proinflammatory lipid mediator leukotriene C4 (LTC4).

132 months revealed an expansion of inflammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, an

133 ariate modeling, no changes were observed in lipid mediator levels, whereas global structural lipids

134 lated by diacylglycerol kinases (DGKs), is a lipid mediator linked to key biologic functions.

135 proresolving lipid mediator lipidomics and/or protein expression, and

136 hromatography tandem mass spectrometry-based lipid mediator lipidomics identified that the n-3 PUFA-d

137 C10 promotes the formation of the resolving lipid mediator lipoxin B4, likely by interfering with AA

138 formyl peptide receptor 2 (ALX/FPR2) by the lipid mediators lipoxin A4 and resolvin D1 (RvD1) promot

139 B1 plus C1q induces specialized proresolving lipid mediators lipoxin A4, resolvin D1, and resolvin D2

140 uction of anti-inflammatory and proresolving lipid mediator, lipoxin A4 (LXA4).

141 Ultimately, lipid mediator (LM) analysis revealed the increased prod

142 ction with marked crosstalk within a complex lipid mediator (LM) network where also specialized prore

143 Herein, we studied bioactive lipid mediator (LM) profiles of tendon-derived stromal c

144 We profiled exudate lipid mediators (LM) via metabololipidomics, CO reduced

145 Other cysteinyl-containing lipid mediators (LMs) derived from docosahexaenoic acid,

146 nce points toward an essential role of these lipid mediators (LMs) in direct regulation of lymphocyte

147 esolution processes and associated bioactive lipid mediators (LMs) mechanistically contribute to this

148 g immunomodulatory eicosanoid and docosanoid lipid mediators (LMs).

149 ury in mice in part through the proresolving lipid mediator LXA4, and LXA4 itself should be considere

150 ENPP2) is the main source of the lipid mediator lysophosphatidic acid (LPA) in biological

151 Here, we report a key role for the lipid mediator lysophosphatidic acid (LPA) in decidualiz

152 The lipid mediator lysophosphatidic acid (LPA) signals via s

153 reted lysophospholipase D that generates the lipid mediator lysophosphatidic acid (LPA), playing a ke

154 Autotaxin (ATX) generates the lipid mediator lysophosphatidic acid (LPA).

155 ges and secretion of the resistance-inducing lipid mediator, lysophosphatidylcholine(24:1).

156 f proinflammatory cytokines, chemokines, and lipid mediators, mainly PGE(2) with induction of cycloox

157 Peptides and lipid mediators may target one or both of these calcium

158 erized by a fundamental reprogramming of the lipid mediator metabolism with macrophages representing

159 In addition, lipid mediator metabololipidomic profiling was performed

160 Mass spectrometry-based lipid mediator metabololipidomics demonstrated that DRV2

161 odel of acute respiratory distress syndrome, lipid mediator metabololipidomics uncovered MaR1 generat

162 In this study, using lipid mediator metabololipidomics with murine joints we

163 itonitis and resolution indices coupled with lipid mediator metabololipidomics, we found that aged mi

164 hromatography-tandem mass spectrometry-based lipid mediator metabololipidomics, we found that PCTR1 i

165 Targeted lipid mediator-metabololipidomics showed that both group

166 sting that supplementation with proresolving lipid mediators might reduce the development of emphysem

167 report that maresin 1 (MaR1), a proresolving lipid mediator, mitigates NASH by reprograming macrophag

168 se results indicate that DGK1 and associated lipid mediators modulate rice root architecture; DAG pro

169 Prostaglandin E2 (PGE2) is a lipid mediator of inflammation, and its tissue concentra

170 et (UV)-irradiated keratinocytes secrete the lipid mediator of inflammation, platelet-activating fact

171 Oxylipins are key lipid mediators of important brain processes, including

172 synthesis of eicosanoids and other bioactive lipid mediators of inflammation and resolution underlyin

173 Lipid mediators of inflammation resolution, e.g., resolv

174 egulated metabolites mapping to pathways for lipid mediators of inflammation.

175 helial migration; and metabolic programs for lipid mediators of lymphocyte motility and chemotaxis.

176 hat the AF concentrations of proinflammatory lipid mediators of the 5-lipoxygenase pathway are signif

177 ammalian biology in the generation of potent lipid mediators of the inflammatory response; consequent

178 Resolvins (Rv), which are highly potent lipid mediators, offer a viable alternative for better t

179 ificant benefits of specialized proresolving lipid mediators on survival and wound healing after majo

180 substrate, produced specialized proresolving lipid mediators, particularly D-series resolvins, which

181 lipid mediators and their relation to other lipid mediator pathways in humans after trauma.

182 poor outcomes after trauma have dysregulated lipid mediator pathways.

183 that the central glycerolipid metabolite and lipid mediator phosphatidic acid (PA) interacts with and

184 was identified to directly interact with the lipid mediator phosphatidic acid (PA).

185 te in vitro results in the production of the lipid mediator platelet-activating factor (PAF).

186 Bioactive lipid mediators play a crucial role in the induction and

187 Lipid mediators play an important role in reproductive b

188 tified for the first time the important role lipid mediators play in both formation and resolution of

189 Eicosanoid lipid mediators play key roles in type 2 immune response

190 Resolvins (Rvs), endogenous lipid mediators, play a key role in the resolution of in

191 atheroprogression, suggesting that resolving lipid mediators potentially represent an innovative stra

192 nstrated that lysophosphatidic acid (LPA), a lipid mediator present in ascites of ovarian cancer pati

193 Maresin 1 (MaR1) is a proresolving lipid mediator produced by macrophages during the resolu

194 "pyroptosis." Leukotriene B(4) (LTB(4)) is a lipid mediator produced quickly (seconds to minutes) by

195 poxydocosapentaenoic acids (EDPs), which are lipid mediators produced by cytochrome P450 epoxygenases

196 d epidermal fatty acids was reflected in the lipid mediators produced, whereas similarities between l

197 ressed ferroptosis, reduced pro-inflammatory lipid mediator production, and inhibited NF-kappaB pathw

198 otomy resulted in an inflammatory peritoneal lipid mediator profile characterized by reduced concentr

199 Divergent shifts in lipid mediator profile following supplementation with n-

200 d EPA have highly divergent effects on human lipid mediator profile, with no overlap in PUFA metaboli

201 sent a viable approach to prevent pathogenic lipid mediator profiles in allergy or asthma.

202 Transcriptional, metabolic, and lipid mediator profiles in macrophages from patients wit

203 These results provide peripheral blood lipid mediator profiles in sepsis that correlate with su

204 d resolvin E1 (RvE1), modulate the bioactive lipid mediator profiles of IL-1beta-stimulated tendon ce

205 Herein, we investigated the bioactive lipid mediator profiles of tendon-derived stromal cells

206 unctive aspirin treatment, we found distinct lipid mediator profiles with increasing disease severity

207 Here, using functional lipid mediator profiling and deeply phenotyped patients

208 ssessment of plasma SPM concentrations using lipid mediator profiling demonstrated a time- and dose-d

209 Aortic lipid mediator profiling of aortas from Apoe(-/-) mice f

210 Herein, using lipid mediator profiling we identified MCTR in human ser

211 on days 3 and 7 thereafter and subjected to lipid mediator profiling.

212 in insights into these mechanisms, we used a lipid mediator-profiling approach to investigate the reg

213 Lipoxins, which are endogenously produced lipid mediators, promote the resolution of inflammation,

214 The endogenous lipid mediator prostaglandin E2 (PGE2) exerts anti-fibro

215 arensis to induce the synthesis of the small lipid mediator prostaglandin E2 (PGE2), which alters the

216 responsible for the formation of the potent lipid mediator prostaglandin E2 under proinflammatory co

217 fts between proinflammatory and proresolving lipid mediators provides a link between metabolic and ce

218 identify how a class of breast milk-specific lipid mediators referred to as alkylglycerols (AKGs) mai

219 tentially widely used mechanism in which key lipid mediators regulate microneme exocytosis.

220 hesis of leukotriene B(4) (LTB(4)), a potent lipid mediator released by neutrophils early during infe

221 emerin and the eicosapentaenoic acid-derived lipid mediator resolvin E1 (RvE1).

222 investigated the actions of two proresolving lipid mediators, resolvin D1 (RvD1) and resolvin D5 (RvD

223 E2, and a concomitant decrease of resolving lipid mediators, Resolvin D2 (RvD2) and Maresin 1 (MaR1)

224 Analyses of lipid mediators revealed increased arachidonic acid and

225 Through its metabolism of the EETs and other lipid mediators, sEH contributes to the regulation of va

226 hma and sinonasal disease severity; however, lipid mediators showed less variability than cytokines.

227 nvolved in the production of proinflammatory lipid mediators showed that 11q-deleted neuroblastoma tu

228 ially if endogenous specialized proresolving lipid mediator signaling is impaired.

229 Fatty acids and lipid mediator signaling play an important role in the p

230 These results reveal dynamic lipid mediator signatures of innate immune cells and pro

231 ose that spatial compartmentalization of the lipid mediator sphingosine 1-phosphate (S1P) may be one

232 activity reporter (aCKAR), we found that the lipid mediator sphingosine 1-phosphate (S1P) promoted th

233 Here, we determined that provision of the lipid mediator sphingosine 1-phosphate (S1P) to the syst

234 Serum levels of the lipid mediator sphingosine-1-phosphate (S1P) are reduced

235 ometry to identify specialized pro-resolving lipid mediators (SPM) in histologically-defined stable a

236 ess orchestrated by specialized proresolving lipid mediators (SPM) that limit the host response withi

237 is, and temporally regulates local levels of lipid mediator/SPM.

238 n of the downstream specialized proresolving lipid mediators (SPMs) 14-hydroxydocosahexaenoic acid, 1

239 Specialized proresolving lipid mediators (SPMs) are endogenous autacoids that act

240 cterized effects of specialized proresolving lipid mediators (SPMs) derived from eicosapentaenoic aci

241 ocess that involves specialized proresolving lipid mediators (SPMs) derived from n-3 (omega-3) fatty

242 Specialized proresolving lipid mediators (SPMs) derived from omega-3 polyunsatura

243 dence suggests that specialized proresolving lipid mediators (SPMs) generated from docosahexaenoic ac

244 rsors of so-called specialized pro-resolving lipid mediators (SPMs), e.g., 17-hydroxy-DHA and 18-hydr

245 Ns]), production of specialized proresolving lipid mediators (SPMs), generation of specific growth fa

246 Specialized pro-resolving lipid mediators (SPMs)-resolvins (Rv), protectins (PD) a

247 ess orchestrated by specialized proresolving lipid mediators (SPMs).

248 Because specialized proresolving lipid mediators (SPMs; lipoxins, resolvins, and protecti

249 ressful, induced a higher production of some lipid mediators such as hydroperoxides and EPA-derived p

250 ed by enhanced production of proinflammatory lipid mediators such as leukotriene B(4).

251 at PAR(2) generates arachidonic acid-derived lipid mediators, such as 5',6'-EET, that activate TRPV4.

252 inflammation; however, it is unclear whether lipid mediators, such as cysteinyl leukotrienes (CysLTs)

253 res biosynthesis of specialized proresolving lipid mediators, such as E-series resolvin (RvE) 1, and

254 testine, it causes the formation of anorexic lipid mediators, such as oleoylethanolamide, which promo

255 The resolution process is regulated by lipid mediators, such as those derived from the omega-3

256 The perturbations of lipid mediators suggested that PFOS has potential negati

257 therapy did not affect circulating levels of lipid mediators, suggesting that pleiotropic effects are

258 This lipid mediator switch represents a novel mechanism of Ox

259 at H1N1 induces surface receptor activation, lipid mediator synthesis, and release of microparticles

260 5 PUFAs, covering pro and anti-inflammatory lipid mediators synthesized across the cyclooxygenase (C

261 Platelet-activating factor (PAF) is a potent lipid mediator that has been implicated in endotoxin-ass

262 Prostaglandin E2 (PGE2) is a pleiotropic lipid mediator that is synthesized from arachidonic acid

263 ligand for 5 specific receptors, is a potent lipid mediator that plays important roles in lymphocyte

264 Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that regulates many processes in inflamma

265 o sphingosine-1-phosphate (S1P), a bioactive lipid mediator that regulates many processes in vertebra

266 esolvin D1 (RvD1), an inflammation-resolving lipid mediator that targets macrophages via its receptor

267 The lipoxins LXA4 and LXB4 are small lipid mediators that act locally to dampen inflammation,

268 well as nonesterified 12(S)-HETE are potent lipid mediators that activate THP-1 human monocytic cell

269 n and are a rich source of newly synthesized lipid mediators that alter vascular permeability and smo

270 eukotrienes (cysLTs) are bronchoconstricting lipid mediators that amplify eosinophilic airway inflamm

271 Prostaglandins are lipid mediators that are involved in a plethora of biolo

272 ase proinflammatory chemokine, cytokine, and lipid mediators that attract further neutrophils and mon

273 entenone prostaglandins (cyPGs) are reactive lipid mediators that bind covalently to proteins and exe

274 Phospholipase A2s generate lipid mediators that constitute an important component o

275 Leukotrienes are proinflammatory lipid mediators that have been shown to be upregulated i

276 have uncovered a new genus of pro-resolving lipid mediators that include the lipoxin, resolvin, prot

277 Lipoxins (LX) are proresolution lipid mediators that inhibit phlogistic neutrophil recru

278 f the D-series are specialized pro-resolving lipid mediators that regulate cellular response by orche

279 and oleoylethanolamide (OEA) are endogenous lipid mediators that suppress inflammation.

280 mediators, called "specialized proresolving lipid mediators," that includes resolvin D1 (RvD1).

281 erosclerosis as both membrane components and lipid mediators, the precise role of sphingolipids in at

282 fferocytosis, and generation of proresolving lipid mediators, thereby prolonging lung inflammation ev

283 on the CYP450 family of epoxygenases and the lipid mediators they produce.

284 mmation, oxidative stress, anti-inflammatory lipid mediators, tissue injury and repair, and growth fa

285 of numerous molecules, from antioxidants and lipid mediators to growth factors, cytokines, and chemok

286 Lipid mediators variedly affect adipocyte differentiatio

287 Several lipid mediators were associated with asthma and sinonasa

288 Following zymosan-initiated inflammation, 18 lipid mediators were identified, including members of th

289 Concentrations of lipid mediators were measured by using liquid chromatogr

290 e 1, type 2, and type 3 inflammation, and 21 lipid mediators were measured in nasal mucus from 109 pa

291 levels of n-3 and n-6 PUFA-derived bioactive lipid mediators were quantified by an unbiased liquid ch

292 lamide (anandamide), a major endocannabinoid lipid mediator, were more susceptible to PTB upon lipopo

293 ve regulates both netrin-1 and pro-resolving lipid mediators, which act in a bidirectional fashion to

294 Herein we discuss a novel class of bioactive lipid mediators, which are enzymatically biosynthesized

295 Our results document the existence of novel lipid mediators, which are involved in the beneficial an

296 Resolvin D1 (RvD1) is a novel proresolution lipid mediator whose effects on inflammatory diseases da

297 Leukotriene B4 is a proinflammatory lipid mediator whose role in peripheral nociceptive sens

298 Lipoxin A4 (LXA4) is an endogenous lipid mediator with compelling anti-inflammatory and pro

299 Lipoxin A4 (LXA4) is an endogenous lipid mediator with potent anti-inflammatory properties

300 4 (LTC4), LTD4, and LTE4 are proinflammatory lipid mediators with pathobiologic function in asthma.